Alnylam on Brink of Profitability Amid FDA Decision
Alnylam, the CEO-led company behind RNAi drug development, is on the cusp of profitability as it awaits an FDA decision that could shift its fortunes. The biotech firm has made significant strides in developing therapies, earning four approvals and pushing forward with innovative treatments. However, despite these achievements, Alnylam remains unprofitable to date. A potential … Read more